Compare Lowe`s Companies Inc (LOW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lowe`s Companies Inc trades at $221.48 (market cap $122.73B), while Regeneron Pharmaceuticals Inc trades at $793.6 (market cap $83.19B). The key difference: Lowe`s Companies Inc is the larger of the two by market cap, and Lowe`s Companies Inc pays the higher dividend (2.28%). Which is the better fit depends on your goals.
| LOW | REGN | |
|---|---|---|
Market Cap | $122.73B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $812.27 |
52-Week Low | $201.92 | $545.94 |
Enterprise Value | $164.48B | $77.90B |
Dividend Yield | 2.28% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $223.35, up 2.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $257.69. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Fundamentals show solid profitability with a net income margin of 7.51% and a P/E ratio of 18.88, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights mixed sentiment, with some institutional selling but optimism around the Pro business segment.
The outlook for LOW is cautiously optimistic, supported by strong analyst buy ratings (60.79%) and a dividend payout. Key risks include competitive pressures, macroeconomic sensitivity, and high debt levels. The upcoming Q2 earnings report on August 19, 2026, will be critical for validating growth expectations and could drive near-term price movement.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
